Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Now Covered by HC Wainwright

Equities research analysts at HC Wainwright began coverage on shares of Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) in a research note issued on Wednesday, MarketBeat.com reports. The firm set a “buy” rating on the stock.

LABT has been the subject of several other research reports. Wall Street Zen upgraded shares of Lakewood-Amedex Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, September 6th. Weiss Ratings upgraded shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research note on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

Lakewood-Amedex Biotherapeutics Stock Down 2.9%

Shares of NASDAQ LABT traded down $0.01 during trading on Wednesday, hitting $0.28. The stock had a trading volume of 1,441,811 shares, compared to its average volume of 1,717,504. Lakewood-Amedex Biotherapeutics has a 12 month low of $0.24 and a 12 month high of $98.20. The firm has a market capitalization of $658,860.00 and a P/E ratio of -0.06. The company’s fifty day moving average price is $1.51.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last posted its earnings results on Friday, August 14th. The company reported ($2.75) earnings per share (EPS) for the quarter. On average, research analysts predict that Lakewood-Amedex Biotherapeutics will post 4.96 earnings per share for the current year.

Lakewood-Amedex Biotherapeutics Company Profile

Lakewood-Amedex Biotherapeutics, Inc is a biotechnology company focused on the research and development of anti-infective therapies. Its work centers on developing treatments designed to address infections caused by bacteria and other pathogens.

The company’s activities are primarily directed toward advancing a pipeline of investigational therapeutic candidates rather than selling a broad portfolio of marketed products. Its development programs have focused on potential applications in human health, including treatments for localized and systemic infections.

Publicly available information about Lakewood-Amedex Biotherapeutics’ current product pipeline, commercial operations, geographic reach, and leadership is limited.